Jonathan Ewbank MA, Biochemistry; PhD, Biophysics; HDR Immunology

Course and current status

1983-1984                   Research Technician, G. D. Searle, High Wycombe, England.

1984-1998                  Undergraduate degree in biochemistry, University of Oxford.

Summer 1985              Research Assistant, G. D. Searle, High Wycombe, England.

Summer 1986              Cadre de Recherche, Laboratoire Roger Bellon, Monts, France.

Summer 1987              Temporary Staff Scientist, Immunex Corporation, Seattle, U.S.A.

1988-1992                   Graduate degree in biophysics, University of Cambridge.

1988-1990                   MRC Laboratory of Molecular Biology, Cambridge, England.

1990-1992                   European Molecular Biology Laboratory, Heidelberg, Germany.

Autumn 1992               Sloan-Kettering Center, New York, U.S.A.

1993-1997                   Postdoctoral Fellow, McGill University, Montreal, Canada.

1997                            Postdoctoral Fellow, CIML, Marseille, France.

1998                            Permanent INSERM position (CR1).

1999                            Junior group leader, CIML, Marseille, France.

2001                            Group leader, CIML, Marseille, France.

2002                            Research Director (DR2), INSERM.

2004-2006                   Director Marseille-Nice Genopole

2006-2010                   Associate Professor at the Université de la Méditerranée

2007-2019                   Research Director (DR1), INSERM.

01/2008-07/2008         Visiting Professor, Dept. Biochemistry, University Oxford, UK.

2012-2015                   Deputy director, CIML

01/2017-08/2017          Visiting scientist, Malaghan Institute for Medical Research, Wellington, NZ

2020-                           Research Director (DRE), INSERM.

2021-                           Director General, European Research Infrastructure on Highly Pathogenic Agents

Scientific summary

After almost 25 years at the CIML, conducting fundamental research into host-pathogen interactions, in 2021 I was appointed Director General of the European Research Infrastructure on Highly Pathogenic Agents, a non-profit organisation that federates maximum- and high-containment laboratories and coordinates or participates in actions to further pandemic preparedness in Europe.

Image d’exemple